Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
The audit was completed with zero critical and zero major observations
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The proposed transaction will be effected as a share swap
Subscribe To Our Newsletter & Stay Updated
